Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the ...

Regeneron has a long history with its gene-sequencing efforts, which likely provides some hints as to why the biotech saw the ...

Intellia's CRISPR therapy nexiguran ziclumeran maintained reductions in the levels of a misfolded protein in the nerves of ...

CellCentric raises $120M Series C for p300/CBP inhibitor inobrodib in multiple myeloma, plans Phase 2/3 trial for accelerated ...

Regeneron is acquiring 23andMe through a court-supervised sale, following 23andMe's bankruptcy filing and recent struggles.

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

The US Supreme Court should decline to review a generic drug labeling fight between Amarin and Hikma Pharmaceuticals because ...

Datavant acquires Aetion in health data merger. Deal doubles life sciences team to 400. CEO Kyle Armbrester says company has ...

Bristol Myers Squibb CEO Chris Boerner said America’s role as the global biopharma leader is at a 'pivot point' as the Trump ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

BioMarin plans to buy Boston-based Inozyme Pharma and its Phase 3 enzyme replacement therapy for about $270 million, the ...